Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Glaxo, Biological E Team On Vaccine
by Lisa M. Jarvis
February 4, 2013
| A version of this story appeared in
Volume 91, Issue 5
GlaxoSmithKline and Hyderabad, India-based Biological E will form a joint venture to develop a six-in-one combination pediatric vaccine that they hope will improve vaccine compliance in the developing world. The vaccine is expected to combine GSK’s polio vaccine with Biological E’s pentavalent vaccine for diphtheria, tetanus, whooping cough, hepatitis B, and Haemophilus influenzae type b. The companies will each contribute a small amount of cash to kick-start discovery work and share development costs. They expect to put the vaccine in Phase I studies within the next two years.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter